US 12,133,886 B2
Method for inducing a tolerogenic immune response
Alan P. Escher, Loma Linda, CA (US)
Assigned to Loma Linda University, Loma Linda, CA (US)
Filed by Loma Linda University, Loma Linda, CA (US)
Filed on Sep. 9, 2020, as Appl. No. 17/015,947.
Application 17/015,947 is a continuation of application No. 14/346,706, granted, now 10,813,987, previously published as PCT/US2012/056761, filed on Sep. 21, 2012.
Claims priority of provisional application 61/538,682, filed on Sep. 23, 2011.
Prior Publication US 2021/0085771 A1, Mar. 25, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 39/02 (2006.01); A61K 49/00 (2006.01); C12N 9/10 (2006.01); C12N 9/22 (2006.01); C12N 9/50 (2006.01); C12N 15/117 (2010.01); C12N 15/70 (2006.01)
CPC A61K 39/0241 (2013.01) [A61K 39/0008 (2013.01); A61K 49/00 (2013.01); C12N 9/1007 (2013.01); C12N 9/22 (2013.01); C12N 9/506 (2013.01); C12N 15/117 (2013.01); C12N 15/70 (2013.01); C12N 2310/17 (2013.01)] 18 Claims
 
1. A composition comprising:
a first methylated polynucleotide encoding a pro-apoptotic protein and having a CpG methylation level of about 15% or less; and
a second methylated polynucleotide encoding an antigen and having a CpG methylation level of about 25%;
for use in the induction of a tolerogenic immune response against the antigen.